Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy samples.


Clinical Trial Description

In the previous "Icemelting" trial, neoadjuvant anti-PD-1 plus anti-VEGFR therapy was used in 20 patients with locally advanced and resectable oral squamous cell carcinoma (OSCC), and the neoadjuvant therapy was well-tolerated, with no grade 3-4 toxicity. The MPR rate was 40% (8/20), including 5% (1/20) pathological complete response; furthermore, in the patients with CPS>10, the MPR rate was 100%. As we know, the MPR might transfer to survival benefit in the patients received neoadjuvant therapy. Therefore, in this randomized phase II trial, we aimed to evaluate the survival benefit of neoadjuvant anti-PD-1 plus anti-VEGFR therapy in the patients with locally advanced OSCC and CPS>10 (Icemelting-2 trial). A total of 46 patients will be enrolled in this trial, and the primary endpoint is 2-year disease-free survival rate. The neoadjuvant therapy arm will receive three cycles of Carrelizumab plus Apatinib with 14 days each, followed by the standard treatment of surgery and postoperative adjuvant therapy. The control arm will received the standard treatment of surgery and postoperative adjuvant therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05069857
Study type Interventional
Source Shanghai Jiao Tong University School of Medicine
Contact Lai-ping Zhong, MD, PhD
Phone +862123271699
Email [email protected]
Status Recruiting
Phase Phase 2
Start date September 1, 2021
Completion date June 30, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT04543266 - Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
Recruiting NCT05024383 - Dissecting the Heterogeneity of Oral Cancer Pain N/A
Not yet recruiting NCT03619304 - Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line N/A
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Recruiting NCT02739204 - Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT04649476 - Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma Phase 2
Recruiting NCT04367909 - A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma Phase 2
Enrolling by invitation NCT01987934 - Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma N/A
Recruiting NCT03502148 - Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT04137627 - Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma Phase 3
Completed NCT03554967 - Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma
Recruiting NCT04718415 - Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Phase 2
Completed NCT03026361 - Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral Cavity N/A
Completed NCT05049408 - Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
Active, not recruiting NCT04413214 - Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial Phase 1
Recruiting NCT03418454 - The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw
Not yet recruiting NCT03345966 - Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study N/A
Active, not recruiting NCT02748707 - Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Phase 2
Recruiting NCT01587573 - Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer
Recruiting NCT01334320 - Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma N/A